Kidney transplant study aims to reduce dangerous side effects from anti-rejection drugs
NCT ID NCT06374095
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times
Summary
This study looks at 75 kidney transplant patients to compare two different anti-rejection drug plans. One group gets a single dose of a drug called RATG, while the other gets seven doses over a week. Both groups also receive other standard medications. The goal is to see which plan causes fewer side effects like low blood cell counts, anemia, and infections, while still protecting the new kidney.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY REPLACEMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24127, Italy
Conditions
Explore the condition pages connected to this study.